Long lasting fusion peptide inhibitors of viral infection
AssigneeConjuChem Biotechnologies Inc.
InventorsDominique P. Bridon, Robert S. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
Life of this patent
Estimating the term…
Abstract
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Claims30
-48. (canceled)
An anti-fusogenic gp41 peptide-albumin conjugate having anti-viral activity against human immunodeficiency virus (HIV), comprising albumin and an anti-fusogenic gp41 peptide that comprises a maleimide containing group and an amino acid sequence, wherein the peptide is covalently bonded to cysteine 34 of the albumin through the maleimide containing group.
An anti-fusogenic gp41 peptide-human albumin conjugate having anti-viral activity against human immunodeficiency virus (HIV), comprising human albumin and an anti-fusogenic gp41 peptide that comprises an amino acid sequence and a maleimide containing group selected from maleimidopropionic acid (MPA) and gamma-maleimide-butyralamide (GMBA), wherein the maleimide containing group is attached to the N-terminus of the peptide or a lysine residue in the amino acid sequence of the peptide via a linker and the peptide is covalently bonded to cysteine 34 of the albumin through the maleimide containing group.
A modified anti-fusogenic gp41 peptide having anti-viral activity against human immunodeficiency virus (HIV), comprising an anti-fusogenic gp41 peptide that comprises a maleimide containing group.
Dependencies are inferred from the claim text.